View Older Stories View More Recent Stories

Aug 9, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
Aug 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
Aug 2, 2022 07:04AM Anavex Life Sciences (AVXL) Reports Long-lasting Effect of ANAVEX3-71 Preventing Cognitive Decline
Aug 2, 2022 07:00AM Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
Jul 31, 2022 10:00AM Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jun 21, 2022 08:00AM Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 8, 2022 07:03AM Anavex Life Sciences (AVXL) Reports Publication Supporting Clinical Biomarker for ANAVEX2-73 in Fragile X Syndrome
Jun 8, 2022 07:00AM Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
May 19, 2022 07:00AM Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
May 10, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
May 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
Apr 27, 2022 07:00AM Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Apr 26, 2022 07:00AM Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Apr 7, 2022 07:00AM Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
Mar 28, 2022 07:00AM Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
Mar 15, 2022 07:00AM Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Mar 9, 2022 07:00AM Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
Mar 4, 2022 07:06AM Anavex Life Sciences (AVXL) Announces Change of Auditor to Grant Thornton LLP
Mar 4, 2022 07:00AM Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
Feb 10, 2022 07:00AM Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 9, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
Feb 4, 2022 07:01AM Anavex Life Sciences (AVXL) Provides Supplemental Information on ANAVEX 2-73 Phase 3 Trial
Feb 4, 2022 07:00AM Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Feb 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
Feb 1, 2022 07:03AM Anavex Life Sciences (AVXL) Reports ANAVEX2-73 AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Feb 1, 2022 07:00AM ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Jan 10, 2022 07:00AM Anavex Life Sciences (AVXL) Reports Positive Phase 1 ANAVEX Results
Jan 10, 2022 07:00AM Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Jan 6, 2022 07:00AM Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
Jan 5, 2022 07:00AM Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dec 14, 2021 07:00AM Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Nov 29, 2021 07:00AM Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 24, 2021 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
Nov 17, 2021 07:00AM Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
Nov 10, 2021 07:00AM Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
Oct 15, 2021 07:00AM Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
Oct 13, 2021 07:05AM Anavex Life Sciences (AVXL) Announces Data Review by Independent Board of its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Oct 13, 2021 07:00AM Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Sep 27, 2021 09:30AM Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
Sep 27, 2021 07:06AM Anavex Life Sciences (AVXL) Announces Uplisting to the NASDAQ Global Select Market
Sep 27, 2021 07:00AM Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
Sep 20, 2021 07:00AM Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 9, 2021 07:00AM Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 26, 2021 07:00AM Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)
Aug 12, 2021 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
Aug 5, 2021 07:00AM Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021
Aug 4, 2021 07:00AM Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
Jul 29, 2021 07:09AM Anavex Life Sciences (AVXL) Announces ANAVEX2-73 Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
Jul 29, 2021 07:00AM Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s
Jun 28, 2021 07:05AM Anavex (AVXL) Announces ANAVEX2-73 Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for th
View More Recent Stories View Older Stories